adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Company profile
Ticker
DMKPQ
Exchange
Website
CEO
Dennis Carlo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Adamis Pharmaceuticals Corp, CELLEGY PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
US Compounding, Inc. • Biosyn, Inc. • Adamis Corporation • Rhombus Pharmaceuticals Corporation ...
IRS number
820429727
DMKPQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
21 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Feb 24
8-K
Bankruptcy or Receivership
5 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
31 Jan 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
8-K
Material Modifications to Rights of Security Holders
23 Jan 24
DEFA14A
Additional proxy soliciting materials
3 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
3 Jan 24
8-K
Regulation FD Disclosure
3 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
Transcripts
DMKPQ
Earnings call transcript
2023 Q1
15 May 23
DMKPQ
Earnings call transcript
2022 Q4
16 Mar 23
DMKPQ
Earnings call transcript
2022 Q3
14 Nov 22
DMKPQ
Earnings call transcript
2022 Q2
11 Aug 22
DMKPQ
Earnings call transcript
2022 Q1
17 May 22
DMKPQ
Earnings call transcript
2021 Q4
31 Mar 22
DMKPQ
Earnings call transcript
2021 Q3
23 Nov 21
DMKPQ
Earnings call transcript
2020 Q3
9 Nov 20
DMKPQ
Earnings call transcript
2020 Q2
20 Aug 20
DMKPQ
Earnings call transcript
2020 Q1
18 May 20
Latest ownership filings
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
John W. Jr. Dorbin
2 Nov 23
3
John W. Jr. Dorbin
2 Nov 23
4
SETH COHEN
25 Oct 23
3
SETH COHEN
25 Oct 23
SC 13D/A
Versi Group LLC
26 Sep 23
4
Ebrahim Versi
19 Sep 23
SC 13G
INTRACOASTAL CAPITAL, LLC
10 Aug 23
SC 13D
Versi Group LLC
5 Jun 23
4
Ebrahim Versi
30 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm | 6.66 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.09 mm | 2.33 mm | 1.25 mm | 781.28 k |
Cash used (since last report) | n/a | n/a | 7.38 mm | 15.79 mm | 8.45 mm | 5.30 mm |
Cash remaining | n/a | n/a | -720.05 k | -9.12 mm | -1.79 mm | 1.36 mm |
Runway (months of cash) | n/a | n/a | -0.7 | -3.9 | -1.4 | 1.7 |
Institutional ownership, Q2 2023
67.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 2 |
Closed positions | 26 |
Increased positions | 1 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 283.37 mm |
Total shares | 6.85 mm |
Total puts | 0.00 |
Total calls | 38.61 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 4.92 mm | $2.39 mm |
Eses Holdings (FZE) | 1.64 mm | $4.33 mm |
Versi | 177.19 k | $443.00 k |
BLK Blackrock | 39.53 k | $95.27 mm |
Vanguard | 30.91 k | $74.49 mm |
Geode Capital Management | 18.95 k | $45.28 mm |
Cubist Systematic Strategies | 13.66 k | $32.91 mm |
Tower Research Capital | 6.97 k | $16.80 mm |
JPM JPMorgan Chase & Co. | 1.68 k | $4.03 mm |
MS Morgan Stanley | 1.36 k | $3.28 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Oct 23 | John W. Jr. Dorbin | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.58 | 70,000 | 40.60 k | 70,000 |
16 Oct 23 | Seth Cohen | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0 | 151,416 | 0.00 | 151,416 |
15 Sep 23 | Ebrahim Versi | Common Stock | Conversion | Acquire C | Yes | No | 0 | 729,200 | 0.00 | 906,394 |
15 Sep 23 | Ebrahim Versi | Series E Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 729.2 | 0.00 | 1,212 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 Feb 24
Crude Oil Moves Higher; Caterpillar Posts Upbeat Earnings
5 Feb 24
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
5 Feb 24
12 Health Care Stocks Moving In Monday's Intraday Session
5 Feb 24
Gold Moves Lower; ISM Services PMI Beats Estimates
5 Feb 24